Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

Background: Clinically-available biomarkers to identify the fraction of patients with small cell lung cancer (SCLC) who respond to immune-checkpoint inhibitors (ICIs) are lacking. High nonsynonymous tumor mutational burden (TMB), as assessed by whole exome sequencing, correlates with improved clinic...

Full description

Bibliographic Details
Main Authors: Ricciuti, Biagio, Kravets, Sasha, Dahlberg, Suzanne E., Umeton, Renato, Albayrak, Adem, Subegdjo, Safiya J., Johnson, Bruce E., Nishino, Mizuki, Sholl, Lynette M., Awad, Mark M.
Other Authors: Massachusetts Institute of Technology. Computational and Systems Biology Program
Format: Article
Language:English
Published: BMJ 2020
Online Access:https://hdl.handle.net/1721.1/128646

Internet

https://hdl.handle.net/1721.1/128646

Similar Items